Telix Pharmaceuticals (OTCMKTS:TLPPF) Trading Down 4.3% – Here’s Why

Shares of Telix Pharmaceuticals Limited (OTCMKTS:TLPPF) fell 4.3% on Wednesday . The company traded as low as $14.75 and last traded at $14.75. 820 shares changed hands during trading, a decline of 88% from the average session volume of 7,026 shares. The stock had previously closed at $15.41.

Telix Pharmaceuticals Stock Down 4.3 %

The stock has a 50-day simple moving average of $14.22 and a 200 day simple moving average of $12.79.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma.